US Equity Markets
GlucoTrack (GCTK) Gains Momentum On Encouraging Clinical Data Release
After GlucoTrack, Inc. (NASDAQ: GCTK) released encouraging results from its first-in-human clinical research, the company’s shares surged 26.25% to $7.84 during the previous session. The results were presented last week in Chicago at the American Diabetes Association’s (ADA) 85th Scientific